These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Sader HS, Jones RN, Washington JA, Murray PR, Gerlach EH, Allen SD, Erwin ME. Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035 [Abstract] [Full Text] [Related]
30. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. Arguedas AG, Arrieta AC, Stutman HR, Akaniro JC, Marks MI. J Antimicrob Chemother; 1991 Mar; 27(3):311-8. PubMed ID: 1903788 [Abstract] [Full Text] [Related]
31. Cefdinir: an expanded-spectrum oral cephalosporin. Guay DR. Ann Pharmacother; 2000 Dec; 34(12):1469-77. PubMed ID: 11144705 [Abstract] [Full Text] [Related]
32. [Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections]. Li JT, Hou J, Kao L. Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):440-3. PubMed ID: 7867436 [Abstract] [Full Text] [Related]
35. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. Schito GC, Georgopoulos A, Prieto J. J Antimicrob Chemother; 2002 Jul; 50 Suppl():7-11. PubMed ID: 12077154 [Abstract] [Full Text] [Related]
36. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases. Bauernfeind A. Diagn Microbiol Infect Dis; 1991 Jul; 14(1):89-92. PubMed ID: 2013215 [Abstract] [Full Text] [Related]